cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
4d Molecular Therapeutics Inc
1 own
3 watching
Current Price
$22.92
$-0.13
(-0.56%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
742.43M
52-Week High
52-Week High
26.49
52-Week Low
52-Week Low
5.32
Average Volume
Average Volume
0.34M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization742.43M
icon52-Week High26.49
icon52-Week Low5.32
iconAverage Volume0.34M
iconDividend Yield--
iconP/E Ratio--
What does the 4d Molecular Therapeutics Inc do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Read More
How much money does 4d Molecular Therapeutics Inc make?
News & Events about 4d Molecular Therapeutics Inc.
Globe Newswire
27days ago
Expands Large Market Ophthalmology Portfolio Following Positive Clinical Data in wet Age-Related Macular Degeneration to Include Diabetic Macular Edema Clinical Program and Geographic Atrophy Preclinical ProgramExpands Large Market Pulmonology Portfolio Following Positive Clinical Data in Cystic ...
Ticker Report
1month ago
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT Get Rating) CEO David Kirn sold 32,933 shares of the businesss stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $23.59, for a total transaction of $776,889.47. Following the completion of the ...
Zolmax
1month ago
4D Molecular Therapeutics (NASDAQ:FDMT Get Rating) and Orchard Therapeutics (NASDAQ:ORTX Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst ...
Benzinga
2 months ago
Latest Ratings for FDMT DateFirmActionFromTo Jan 2022SVB LeerinkInitiates Coverage OnOutperform Jan 2021B of A SecuritiesInitiates Coverage OnBuy Jan 2021Goldman SachsInitiates Coverage OnNeutral View More Analyst Ratings for FDMT View the Latest Analyst Ratings read more...
Globe Newswire
3 months ago
Cohort 1 lung bronchoscopy sample results demonstrate widespread delivery and expression of the 4D-710 CFTRR transgene in 100% of samples from all three patients Cohort 1 safety and tolerability of 4D-710 demonstrated to date, with no drug-related adverse events following aerosol deliveryCohort 1 ...
Frequently Asked Questions
Frequently Asked Questions
What is 4d Molecular Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy 4d Molecular Therapeutics Inc shares?
plus_minus_icon
How can I buy 4d Molecular Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of 4d Molecular Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in 4d Molecular Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of 4d Molecular Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of 4d Molecular Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of 4d Molecular Therapeutics Inc?
plus_minus_icon
What percentage is 4d Molecular Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is 4d Molecular Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$22.92
$-0.13
(-0.56%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00